Eagle Pharmaceuticals (EGRX) said Wednesday it has licensed rights to develop, market and sell injection products for blood cancers to Tokyo-based SymBio Pharmaceuticals.

The company said SymBio will be responsible for obtaining regulatory approval of Eagle’s bendamustine hydrochloride (bendamustine HCI) ready-to-dilute and rapid infusion injection products in Japan, with a target for product approval in 2020.

Under the terms, Eagle said it will receive a $12.5 million upfront milestone payment from SymBio, adding it may be entitled to additional milestone payments upon approval and the achievement of sales thresholds. Eagle also said it will receive royalties on future net sales of the licensed bendamustine products.

Currently, SymBio markets Treakisym in Japan, which is a lyophilized powder formulation of bendamustine HCI for chronic lymphocytic leukemia, relapsed or refractory low-grade Hodgkin’s lymphoma, mantle cell lymphoma and as a first-line treatment for low-grande Hodgkin’s lymphoma and mantle cell lymphoma.

Eagle noted that a 50 ml rapid infusion presentation of bendamustine hydrochloride injection is currently marketed in the US by Teva Pharmaceutical Industries (TEVA) as Bendeka injection.

Fatal error: Call to undefined function printFooterForm() in /home3/boost/public_html/westoverreview.com/wp-content/themes/alpha/single.php on line 57